NR4A1 and breast carcinoma: In contrast, our 17-gene signature was specifically developed to distinguish complete responders from non-responders across all breast cancer molecular subtypes, not restricted to hormone receptor-positive cases, reflecting the broader application of NAC in contemporary clinical practice [37].